Form 4: Mainz Biomed Director Receives 45,000 Restricted Shares

Mainz Biomed N.V. Director Heinrich Dreismann was granted 45,000 restricted ordinary shares under the company's 2025 Omnibus Incentive Plan.

Summary

• Director Heinrich Dreismann of MAINZ BIOMED N.V. acquired 45,000 ordinary shares.
• These shares were granted as restricted shares under the company's 2025 Omnibus Incentive Plan, with no cash consideration paid.
• Following this transaction, Dreismann beneficially owns a total of 64,700 ordinary shares.
• This total includes 19,700 ordinary shares that originated from employee stock options previously granted and reported on a Form 3 filed on January 26, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating management's continued commitment and alignment with shareholder interests through equity ownership, which is a standard practice.

Positives

• The grant of 45,000 restricted shares to Director Heinrich Dreismann aligns management's interests with those of shareholders.
• The use of an Omnibus Incentive Plan suggests a structured approach to executive compensation and retention.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• NA

Industry Context

StockSavvy.ai notes that insider share grants are a common mechanism in the biotech/pharma industry to incentivize long-term commitment and align leadership with company performance, especially for directors.

Comparison to Industry Standards

• StockSavvy.ai observes that granting restricted shares as part of an incentive plan is a standard practice across various industries, including biotechnology, for executive compensation and retention.
• Companies like Pfizer (PFE) and Moderna (MRNA) frequently utilize similar equity-based compensation structures to motivate key personnel and align their interests with shareholder value creation.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Grant of 45,000 restricted ordinary shares to Director Heinrich Dreismann by MAINZ BIOMED N.V. under the 2025 Omnibus Incentive Plan.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of director's interests with company performance.
• Employees: The existence of an Omnibus Incentive Plan suggests a broader framework for employee incentives, potentially boosting morale and retention.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 reports a routine grant of restricted shares to a director as part of an incentive plan, which is a standard practice for aligning management interests with shareholder value. While it indicates continued commitment from leadership, it does not present new fundamental information that would significantly alter the investment thesis for MAINZ BIOMED N.V., thus warranting a 'hold' recommendation for existing investors.

Keywords

MAINZ BIOMED, MYNZ, insider transaction, Form 4, director compensation, restricted shares, stock grant, equity incentive plan